Vera Therapeutics

Yahoo Finance • 7 days ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 10 days ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 26 days ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction... Full story

Yahoo Finance • 26 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards con... Full story

Yahoo Finance • 28 days ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)The safety profile of atac... Full story

Yahoo Finance • 29 days ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025Biologics License... Full story

Yahoo Finance • last month

Is Waystar a Buy After Investment Company Capricorn Fund Managers Makes the Stock Its Top Holding?

Key Points Capricorn Fund Managers initiated a position in Waystar with 505,122 shares acquired, estimated at ~$19.15 million based on the average price during Q3 2025. The Waystar stake represents 6.4% of Capricorn Fund Managers' 13F rep... Full story

Yahoo Finance • 2 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 2 months ago

Stocks of possible M&amp;A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 4 months ago

Wolfe Research downgrades Vera Therapeutics stock rating on limited catalysts

Investing.com - Wolfe Research downgraded Vera Therapeutics (NASDAQ:VERA) from Outperform to Peerperform on Monday. According to InvestingPro data, the company maintains a FAIR financial health score, with analysts setting price targets... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase... Full story

Yahoo Finance • 5 months ago

Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal

There’s a current of optimism in the air as Wall Street’s stock markets climb back to record levels, with the S&P 500 hitting an all-time high yesterday. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off!... Full story

Yahoo Finance • 5 months ago

Thursday 6/26 Insider Buying Report: VERA, GMRE

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics director Enright buys shares worth $5.2m

Director Patrick G. Enright of Vera Therapeutics , Inc. (NASDAQ:VERA) recently purchased shares of Class A Common Stock. On June 23 and 24, 2025, Enright acquired a total of 250,690 shares at prices ranging from $20.8683 to $22.3517, resu... Full story

Yahoo Finance • 6 months ago

Vera plunges as Otsuka outperforms with IgA nephropathy therapy

[USA Recession and Crashing Economy Concept] mphillips007 Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) fell ~32% in the premarket on Friday after late-stage trial data indicated that the company’s lead asset, ata... Full story

Yahoo Finance • 6 months ago

Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans

* Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) Tuesday announced [https://seekingalpha.com/pr/20123922-vera-therapeutics-announces-refinancing-of-existing-oxford-debt-facility-providing-up-to-500] that it has en... Full story

Yahoo Finance • 6 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Vera Therapeutics BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with seri... Full story

Yahoo Finance • 6 months ago

Vera rises after success in late-stage trial for IgA nephropathy treatment

[Human Kidneys - Medical Illustration] peterschreiber.media/iStock via Getty Images Shares of Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) rose after the company said on Monday it achieved its main goal in a late... Full story

Yahoo Finance • 6 months ago

Why Vera Therapeutics Is Rising In Pre-market?

(RTTNews) - Vera Therapeutics (VERA) announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy in adults. Participants treated with atacicept achieved a 46% reduc... Full story

Yahoo Finance • 6 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other... Full story